AnaptysBio Inc
NASDAQ:ANAB 4:00:00 PM EDT
| Market Cap (Intraday) | 515.73M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $20.36 |
| 50-Day MA | $23.02 |
| 200-Day MA | $20.06 |
AnaptysBio Inc Stock, NASDAQ:ANAB
10770 Wateridge Circle, Suite 210, San Diego, California 92121-5801
United States of America
Phone: +1.858.362.6295
Number of Employees: 117
Description
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.